Slides
Page 1
Sai Life Sciences Limited Investor Presentation February 06, 2026
Page 2
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. 2
Page 3
Executive Summary
Page 4
4 Message from Managing Director & CEO Mr. Krishna Kanumuri MD & CEO Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. During the quarter, we strengthened our technology platforms through greater adoption of digital, AI-enabled and modern chemistry approaches, enhancing our ability to support increasingly complex programs for global innovator clients. In parallel, we continued to build organizational depth by adding experienced scientific and leadership talent, ensuring our teams scale in step with our expanding capabilities. Our capacity expansion plans remain firmly on track, with manufacturing scale-up and process development infrastructure progressing in line with our long-term roadmap. These investments are being guided by the evolving scientific contours of next-generation medicines and the changing needs of our customers. Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders. “ “
Page 5
5 Message from Whole-time Director and Chief Financial Officer Mr. Siva Chittor Whole-time Director & CFO We have delivered a robust growth in Q3FY26 which outperformed the broader CRDMO industry trend, with improved operating performance, driven by disciplined execution and healthy momentum across our businesses. For the quarter, total revenue stood at ₹556 Cr, representing a 27% year-on-year increase, supported by sustained demand and healthy volume growth across key service lines. EBITDA grew by 54% year-on-year to ₹191 Cr, with margins expanding by 605 bps to 34%, supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives. As of date, we have invested ₹405 Cr in capital expenditure, aligned with our long-term strategy to strengthen capabilities and expand capacity. This investment remains in line with our guided FY26 capex plan and reinforces our commitment to building scalable, future-ready infrastructure. We continue to focus on prudent capital allocation and margin discipline while investing selectively in areas that enhance our differentiated value proposition. With strengthened capabilities, a solid order pipeline, and a more resilient operating foundation, we are well positioned for another year of strong and profitable growth, creating enduring value for our stakeholders. “ “
Page 6
Business Highlights 6 Global macros continue to favour India as an outsourcing destination • Significant increase in strategic conversations with large pharma innovators; expect a healthy growth trend to continue into the next year CRO Business Growth and Technology Advancement • The CRO business continues to maintain strong growth momentum, supported by focus on increasing contributions from large pharma • Investing in new technology capabilities to accelerate Discovery CDMO Growth and Pipeline Strengthening • The CDMO business continues to perform well, with 90%+ of contributions coming from pharma • Larger pool of late phase and commercial molecules help business offset impact of volume variability on individual molecules that are outside the control of a CDMO • Added 7 molecules to the late phase and commercial pipeline during the year, taking the total to 43 molecules Capex Progress Inline with the plan • Invested ₹405 Cr as on date in capital expenditure, against a plan of ₹700 Cr for FY26 • R&D facilities • Additional MedChem capacity (200 fume hoods) to be commissioned in Q4FY26 • Process R&D Lab structure completed – commissioning by Sep 26 • Peptide process and pilot plants commissioning scheduled for Sep 26 and will help expand our work in the peptide space from Discovery to Process & scale up • OEB 6 labs for Discovery (phase 1 completed); OEB 6 labs for process development underway and expected to completed in October 26; these labs will expand our work in the new gen ADCs • Manufacturing • ~450KL capacity expansion ongoing, one production block with 225 KL capacity to be commissioned by Q2FY27; 2nd block by end of FY27 • Phase I Animal health expansion to be completed by Mar 27; expect to begin validation for a commercial launch shortly thereafter
Page 7
Business Highlights 7 AI & Digital Platforms • Working on building out an end-to-end AI-driven pharma services business to sustain competitive advantage; details to be shared at an appropriate time • Applied AI driven retrosynthetic analysis to ML generated compounds, accelerating route design and improving synthetic efficiency • Successfully delivered a full library of AI designed macrocyclic peptides, demonstrating AI’s role in complex modality generation Technology Adoption & Infrastructure Scale-Up • Created a centralized group for Photochemistry and Electrochemistry, enabling broader adoption of modern reaction technologies • Strengthened Flow capabilities across Discovery & CMC; successfully scaled late-phase photo flow bromination; next GMP plug-flow step commencing Quality and Compliance Excellence • Successfully completed 8 customer audits across manufacturing and R&D units, with zero data integrity deviations and zero critical observations Sustainability • Released 6th Sustainability Report 2024-25, outlining progress against ESG priorities • Achieved My Green Lab (MGL) Green-level certification for two Process R&D laboratories and two Medicinal Chemistry laboratories, with over 98% compliance - the highest standard under the MGL framework • Published a joint sustainability case study with Bayer on The Climate Drive, highlighting the increased adoption of a hybrid solar–wind captive power model at the Bidar manufacturing site under a long-term power purchase agreement (PPA)
Page 8
Consolidated Financial Highlights (Quarterly) 8 Revenue (₹ Cr) Material Margin (₹ Cr) and Margin (%) 440 556 Q3FY25 Q3FY26 319 429 72.5% 77.0% Q3FY25 Q3FY26 EBITDA (₹ Cr) and Margin (%) PAT (₹ Cr) and Margin (%) 124 19128.3% 34.4% Q3FY25 Q3FY26 Q3FY26 Revenue Contribution 65% 35% • Revenue for Q3FY26 was ₹556 Cr, a 27% increase over ₹440 Cr in Q3FY25, driven by strong growth both in CRO and CDMO services • CDMO recorded revenues of ₹361 Cr in Q3FY26, up 31% from ₹276 Cr in Q3FY25 • CRO recorded revenues of ₹195 Cr in Q3FY26, up 19% from ₹164 Cr in Q3FY25 • EBITDA for Q3FY26 stood at ₹191 Cr compared to ₹124 Cr in Q3FY25, an increase of 54% • EBITDA margin improved by 605 bps to 34% in Q3FY26 • PAT for Q3FY26 increased to ₹100 crore, registering a growth of 86% YoY as compared to ₹54 crore in Q3FY25 CDMO CRO 54 100 12.2% 18.0% Q3FY25 Q3FY26 27% YoY 34% YoY 54% YoY 86% YoY
Page 9
Consolidated Financial Highlights (Nine Months) 9 Revenue (₹ Cr) Material Margin (₹ Cr) and Margin (%) 1,115 1,590 9MFY25 9MFY26 817 1,181 73.3% 74.3% 9MFY25 9MFY26 EBITDA (₹ Cr) and Margin (%) PAT (₹ Cr) and Margin (%) 82 2457.3% 15.4% 9MFY25 9MFY26 264 47223.7% 29.7% 9MFY25 9MFY26 9MFY26 Revenue Contribution 65% 35% • Revenue for 9MFY26 was ₹1,590 Cr a 43% increase over ₹1,115 Cr in 9MFY25 • CDMO recorded revenues of ₹1,028 Cr in 9MFY26, up 55% from ₹663 Cr in 9MFY25 • CRO recorded revenues of ₹562 Cr in 9MFY26, up 24% from ₹452 Cr in 9MFY25 • EBITDA for 9MFY26 rose to ₹472 Cr compared to ₹264 Cr in 9MFY25, an increase of 79% • EBITDA margin expanded by 601 bps YoY to 30% in 9MFY26 mainly due to operating leverage on employee costs 450 bps and material margin 100 bps • PAT for 9MFY26 increased to ₹245 crore, registering a growth of 199% YoY as compared to ₹82 crore in Q3FY25. • Invested ₹405 crore in capital expenditure, against a plan of ₹700 Cr for FY26 CDMO CRO 43% YoY 45% YoY 79% YoY 199% YoY
Page 10
Sustained Growth Momentum with Expanding Profitability 870 1,217 1,465 1,695 15% 15% 20% 25% FY22 FY23 FY24 FY25 IPO Positioned to achieve 15-20% revenue CAGR over 3-5 years* & 28 - 30% EBITDA margins in the next 2-3 years* 1,115 1,590 24% 30% 9MFY25 9MFY26 Revenue (₹ Cr) EBITDA Margin (%) (Consolidated) 10 Note: * Base year FY2025 With 9MFY26 EBITDA at 30%, we are on course to achieving our stated goal of 28-30% EBITDA ahead of schedule. We expect to sustain this margin range (28-30%) to enable us maximise growth while managing growth related challenges and optimising margins.
Page 11
Company Overview
Page 12
Sai Life Sciences: At a Glance 25+ Years of Expertise Founded in 1999, Sai Life Sciences has transformed into an integrated CRDMO, delivering value across the pharma lifecycle from early discovery to commercial manufacturing Global Partner of Choice Trusted by 300+ global clients, including 18 of the top 25 global pharma companies across the US, UK, EU, and Japan Expansive Infrastructure World-class R&D and manufacturing facilities across Hyderabad, Bidar, Manchester, and Boston, with ~700 KL of installed capacity Innovation-Led Growth Focused investments in next- gen modalities like Peptides, ADCs, Oligos and TPDs; empowered by digital transformation, automation, and AI/ML to accelerate delivery and differentiation 12
Page 13
Key Highlights 3,400+ Total employees USFDA, PMDA 100% successful track record of regulatory inspections across our R&D and manufacturing facilities. 300+ Active customers across US, UK, EU, Japan Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more 10+ Years: Enduring customer relationships 18/25 of the largest pharmaceutical companies are customers 30 Commercial molecules >65% Integrated Drug Discovery Services 18 months Demonstrated time from Hit to IND 25+ Years of experience (Incorporated in 1999) One-stop platform for discovery, development and manufacturing 40+ Programs advanced to IND or Phase I/II/III 5 Molecules from discovery to market 6 Phase III/ pre-registration 13 Note: As on March 2025
Page 14
Global Presence 14 Strategically located to combine innovation access, client proximity, and cost efficiency Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India Sai Facilities Presence Exploratory Biology Lab in the Cambridge-Boston Life Sciences ecosystem Boston Manchester Process R&D Lab in Alderley Park Bidar Hyderabad 700 KL GMP Manufacturing 13-acre Integrated R&D Campus in Genome Valley Global Delivery Model
Page 15
Our Growth Journey • Incorporated in 1999; began as a medicinal chemistry partner to US biotech firms • Expanded into Process R&D and small-scale manufacturing aligned with the needs of Biotechs clients • First USFDA approval of Unit IV • Expanded R&D (Unit II) to enable large-scale pharma CDMO services • Added 100 KL capacity at Unit IV • Animal facility received AAALAC accreditation • Cleared USFDA & PMDA audits at multiple sites • Integrated Biology services; becoming end-to-end Discovery partner • Added >120 KL (PB-07) and >170 KL (PB-08) blocks at Unit IV • Entered global markets: labs in Manchester & Boston • Commissioned Clean Room, Amidites, and HPAPI blocks at Unit IV • Strategic partnership with Schrödinger to enhance discovery science • Continued regulatory track record and expansion of global footprint • Listed on NSE & BSE • Construction underway for new MedChem block with 200 fume hood capacity • Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early phase peptide development and clinical formulations • Commenced work on building additional 200kL production capacity at Unit IV, Bidar 1999 - 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & Early Biotech Foray CDMO Pivot CDMO Consolidation, Biology Foray Globalization, Scaled-up Integrated CRDMO Increasing Capacity & Strengthening New-Age Modalities 15
Page 16
A leading CRDMO with scaled operations across both verticals 16 Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies • Medicinal Chemistry & Computational Drug Discovery • Biology & Pharmacology Research • DMPK & Toxicology Studies • Preclinical Research & IND Filing • Process Development & Optimization • Analytical Development & Validation • Formulation Development & Stability Studies • Clinical Trial Supplies (Phase I-III) • Regulatory Compliance & Quality Assurance • API (Active Pharmaceutical Ingredient) Manufacturing • Technology Transfer & Scale-Up • Commercial Production & Global Supply Chain • Regulatory-Compliant Manufacturing (US FDA, PMDA, COFEPRIS) Phase 1 DISCOVERY (CRO) Phase 2 DEVELOPMENT (CRO & CDMO) Phase 3 MANUFACTURING (CDMO) Seamless Integration – One-stop solution from research to commercial production Regulatory Excellence – Compliant with global standards (US FDA, PMDA, COFEPRIS) Scalable & Flexible – Supporting emerging biotech & leading pharma companies
Page 17
Discovery Services (CRO) 17 Notes: (1) Last 5 years (2) Discovery services (including chemistry, biology and/or DMPK services) Consistent Revenue Growth (₹ Cr) 189 274 467 497 626 FY21 FY22 FY23 FY24 FY25 Client Stickiness >65% Revenues from customers in FY23-25 who availed more than one Discovery services(2) Dedicated Facility Among the few CROs with a dedicated facility for a global innovator, now scaled up by 30% to support growing demand and deeper integration. Modalities Expansion Expanding capabilities in ADCs, TPDs, Peptides, CGTs, Oligos, and more. 33% 38% 67% 62% FY24 FY25 Pharma Biotech Customer Split %
Page 18
Discovery Services: Scaling Innovation, Driving Impact 18 >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Technology advancements are transforming Sai’s Discovery platform into a scalable, high-value growth engine Expanded Core Capabilities Scaled Chemistry, Biology, DMPK, and In Vivo labs delivering faster, parallelized research Colocalized & Global Teams Hyderabad campus and Boston Biology Lab enable seamless collaboration and rapid tech transfer Tech-Enabled Drug Discovery AI-enabled retrosynthesis tools High-throughput Experimentation DMPK automation CADD in silico tools Specialized Modalities Peptides, ADC payloads, Oligos, TPDs and driving high-value Discovery growth Next-Gen Preclinical Models Organoids and spheroids enable predictive, FDA- aligned efficacy and toxicity testing
Page 19
CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India • Flexibility to support both small-scale clinical supplies and large-scale commercial production. • Proven track record of commercializing NCEs • Robust regulatory record with USFDA and PMDA • 160 Programs in the pipeline across multiple therapy areas • Clear Regulatory Record: USFDA, PMDA • At the forefront of digitalization, automation and sustainability Business Mix Revenue Contribution – By Therapy (%) 571 596 760 968 1,068 FY21 FY22 FY23 FY24 FY25 Note: Therapy area contribution varies year-to-year based on client portfolio mix and project timelines. Not indicative of overall market trends Consistent Revenue Growth (₹ Cr) 11% 11% 8% 14% 22% 7% 3% 4% 4% 17% 21% 18% 12% 10% 10% 9% 4% 3% 3% 10% CNS Infectious Diseases Cardiovascular Anti Histamine Oncology Metabolic Disorders Genetic Disorders Dermatology Immunology Others FY24 FY25 79% 91% 21% 9% FY24 FY25 Pharma Biotech Customer Split % 19
Page 20
New Modalities: Fortifying foundation to build scale 20 4% 3% 3% 7% FY22 FY23 FY24 FY25 New Modalities Revenue Contribution (%) Peptides Complement peptide discovery with process and scale-up facilities for clinical supplies; focus on commercial supply of fragments before evolving to full-scale peptide manufacturing. Antibody-Drug Conjugates Enhancing conjugation in Discovery; upgrading to class 6 containment for end-to-end support. Evaluating clinical conjugation and fill-finish for clinical supply Oligonucleotides Involved in multiple projects with Pharma from development to commercial; to focus only on making amidites. Lipids Involved in supplying lipids for last few years; looking to expand capacity
Page 21
Our Strengths
Page 22
Strategic Growth Levers & Competitive Edge Deeper Customer Engagement Expanding Capacity & Capabilities Global Footprint, Local Advantage Quality & Sustainability Leadership Technology-Driven Efficiency Talent & Innovation Culture 22
Page 23
Information Technology - Driven Excellence: Digitization & Beyond Digitization 2017 onwards Digitalization 2022 onwards Digital Transformation 2023 onwards Converting data, documents and processes from paper/ analog to digital integration of digital technologies into all aspects of business operations Use of digitized data for effective monitoring through visual interactive dashboards. • GMP Pro and ELN implementation • QR Code & Label Management • Learning Management System • Audit Management System • Laboratory Information Management System • Validation Life Cycle Management System • Batch Quality, Yield, Experiments, Equipment Occupancy, Staffing status, QMS, etc. • Digital Transformation Initiatives • AI/ML - Manufacturing Process Prediction Model R&D and Mfg processes progressively digitized to current levels of 85% digitization Interactive Business Intelligence dashboards created using real-time data across functions and use cases. Leveraging large data sets with AIML models to create prediction models. Looking Ahead • Digitization process expected to be complete by 2027 • Continued adoption of BI models to aid faster decision-making • AI/ML model proof-of-concept outcome to emerge in 2026. • Based on results, further integration into operations will be undertaken. 23
Page 24
Global-Standard Operations, End-to-End Quality Assurance • 285+ QA/QC professionals across sites • Integrated e-systems: LIMS, e- QMS • QA independent; reports to CEO • Audited by USFDA, EMA, PMDA, Indian regulators • Focus on data integrity & global compliance Sustainability Leadership • 89% renewable energy at Bidar site • Zero Liquid Discharge: water- neutral ops • Carbon roadmap approved by SBTi • Low-emission logistics via DHL Safety & EHS Leadership • Embedded Process Safety from quote to execution phase; rigorous lifecycle safety assessments. • Plant Intermediates areas & lab fume cupboards validated down to 1 µcg/ m3 containment • First Indian company to join the PSCI membership; >30 PSCI Audits over the past 7 years • Silver rating by EcoVadis 24
Page 25
Key Drivers for Growth Scaling Capacity & Infrastructure • The company continue to make strategic capital investments in line with its annual capex plan of ~ ₹700 Cr for FY26 to enhance manufacturing and R&D infrastructure, including development of a second manufacturing site in Hyderabad. • These strategic investments will nearly double Sai’s overall manufacturing capacity by FY27, while diversifying its footprint and reducing concentration risk Diversifying Portfolio • 36 active molecules* –30 commercial, with 6 Phase III / pre registration • 160 in early phase development • Established model for a dedicated partnerships • Average tenure of large pharma relationships is ~10 years • 200+ clients, 60+ integrated collaboration under discovery Scientific & Talent Leadership • Driving global program transfers to India across discovery, development & manufacturing • Rapidly expanding leadership bench with experts from top CDMOs and global pharma • Strengthening capabilities in new modalities, enabling pipeline expansion and stickier client relationships • Building future-ready teams aligned to Sai’s scale-up and innovation roadmap * Excluding molecules under destocking and low value molecules with limited potential 25
Page 26
Expansion Plans
Page 27
Capacity Expansion Underway: Scaling from 700 KL to 1,150 KL by 2026 27 16 40 105 230 450 475 700 1,150 0 200 400 600 800 1,000 1,200 1,400 2009 2011 2013 2017 2021 2023 2025 2026 Reactor capacity in KL Unit 3 & Unit 4 Blocks 1-6 PB07 Intermediate Block PB08 Intermediate PB09 clean room blocks PB 10 high potency & PB 12 amidite blocks PB 11 Intermediate block & unit 06 animal health API block PB 14 & 15 Intermediate Block in 5.9 Acre U4 ext
Page 28
CMC Process R&D Block 28 Sai Life Sciences has commenced construction of a new CMC Process R&D Center at its Hyderabad campus, targeted for completion by September 2026. The facility will double Process R&D capacity. Designed to support both FTE and DPC engagement models, it will offer flexible collaboration for global innovators across early to late-stage CMC programs. ▪ Specialized labs for peptides and Amidites ▪ Kilo Lab for early clinical supplies ▪ NCE Formulation Development & Early Phase Clinical Supplies ▪ Designed to meet OEL 4 (1 µg/m3) band ▪ Process R&D lab and Scale up Lab ▪ ~140 process chemistry fume hoods with satellite analytical lab ▪ Buildup area ~100K Sq.Ft across 5 floors with Green building Certification ▪ 25,000 sft of Analytical Lab under a single roof Note: FTE- Full Time Equivalent. DPC- Discovery Process Chemistry
Page 29
Industry Overview
Page 30
The CRDMO industry is a Service Business with value drivers different from generic pharma companies As a CRDMO, our value doesn’t hinge on drug approvals - we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long term client partnerships. - Krishna Kanumuri, MD & CEO • R&D investments in drug discovery / development program translate to revenue opportunities for CRDMOs – irrespective of whether it receives approval or not • Stage-gating decisions rest with the innovator (clients) • Given the multitude of factors involved, the success or failure of a molecule is never directly attributed to the CRDMO. • CRDMOs are purely judged by the quality of work they render within the scope of the defined project “ “ 30
Page 31
Global CRDMO Industry Set to Cross USD 300 Bn by 2028 31 Global CRDMO Market (USD Bn) 127 196 303 2018 2023 2028E Global CRDMO Market by Modality (USD Bn) 106 153 22521 44 77 2018 2023 2028E Large molecule Small molecule • Global CRDMO market projected to reach USD 303 Bn by 2028 (9% CAGR 2023-2028) • 50%+ of pharma R&D budgets outsourced to CRDMOs, driving structural growth • Biologics, peptides, and oligonucleotides expected to drive ~40% of total growth by 2028 • Large molecule CRDMO segment growing fastest (12% CAGR 2023 - 28), supported by biologics demand • Asia-Pacific market projected to grow at 12% CAGR (2023–28) - the fastest among all regions, outpacing Europe (10%) and North America (5%) With growing investments in Peptides, Oligos & ADCs, Sai Life Sciences is positioned to capture growth in the fastest- expanding CRDMO segments globally Source: Frost & Sullivan
Page 32
India Rising as a Strategic CRDMO Hub 32 Indian CRDMO Market (USD Bn) 4 7 14 2018 2023 2028E Global CRDMO Market by Modality (USD Bn) 4 7 13 0 1 1 2018 2023 2028E Large molecule Small molecule • Indian CRDMO industry is among the fastest-growing worldwide, projected to grow at 14% CAGR (2023–28) • By 2028, CDMO is expected to contribute ~75% of India’s USD 14 Bn CRDMO market, growing to USD 11 Bn, while CRO expands to USD 3 Bn • Cost efficiency (30–40%) with global-standard quality is making India the preferred outsourcing destination for pharma sponsors Sai Life Sciences is scaling capacity, innovation, and specialty modalities to leverage India’s rising global CRDMO share and China- to-India outsourcing shift. Source: Frost & Sullivan
Page 33
Annexure
Page 34
Consolidated Statement of Profit and Loss 34 Particulars (₹ Cr) Q3FY26 Q2FY26 Q3FY25 9MFY26 9MFY25 FY25 Revenue from operations 556 537 440 1,590 1,115 1,695 Other income 5 5 4 17 11 18 Total income 561 543 444 1,607 1,126 1,712 Expenses Cost of materials consumed and changes in inventories 128 140 121 409 298 466 Employee benefits expense 173 163 133 496 398 549 Other expenses 681 89 66 230 171 274 Forex (gain)/loss (3) (10) (5) (17) (16) (19) EBITDA 191 156 124 472 264 425 EBITDA Margin 34% 29% 28% 30% 24% 25% Finance costs 10 9 23 31 65 76 Depreciation and amortisation expense 44 40 34 122 101 139 Profit before tax & exceptional Item 142 112 72 335 109 228 Exceptional Item, loss2 8 - - 8 - - Profit before tax 134 112 72 327 109 228 Tax expense 34 28 18 82 27 58 Profit after tax 100 84 54 245 82 170 1. Includes ₹16 Cr being partial reversal of provision taken last year on early intermediate of a commercial product on account of de-stocking. The customer has renewed orders and we have reversed the provision to the a extent of material dispatch. Revenues and margin on this product will be accretive going forward. 2. Exceptional loss due to change in wage definition resulting in an increase in gratuity and leave provision.
Page 35
Awards Certificates & Accreditations 35 ISO 14001:2015, ISO 45001:2018 & ISO 50001:2018 certification Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013 Affiliations with Leading Industry organizations: Signatory of United Nations Global Compact (UNGC) Eco Vadis Silver Medal for Sustainability CII-SR EHS Excellence Award for 5 Years GSK’s Environmental Sustainability Supplier award 2021 in ‘Primary Manufacturing’ category
Page 36
Glossary 36 APIs Active pharmaceutical ingredients Biotechs Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023 CDSCO Central Drug Standards Control Organization, India CMC / CDMO Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization CMO Contract Manufacturing Organization COFEPRIS Mexico Federal Commission for the Protection against Sanitary Risk of Mexico CRDMO Contract Research, Development, And Manufacturing Organization CRO Contract Research Organization DMPK Drug metabolism and pharmacokinetics GATT General Agreement on Tariffs and Trade Generic drugs Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires Innovation Clusters/Hubs Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs Innovator Drugs Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use Large Molecule Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes Large Pharma Companies Pharma companies with revenues > USD 10 billion Mid Pharma Companies Pharma companies with revenues in range of USD 500 million to USD 10 billion NCE New chemical entities PMDA Pharmaceuticals and Medical Devices Agency, Japan Small Molecule Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes Small Pharma Companies Pharma companies with revenues lower than USD 500 million TRIPS Trade-Related Aspects of Intellectual Property Rights UNIT IV Manufacturing facility at Bidar USFDA United States Food and Drug Administration
Page 37
© Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India. For more details please contact: Investorrelation@sailife.com Thank You